Displaying 141 - 160 of 853
| Active Ingredient | CARBOPLATIN |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Advanced ovarian cancers and of small-cell lung cancer. |
| Caution | As for cisplatin. Myelosuppression may be more severe than cisplatin and prolonged in patients with impaired renal function. |
| Dose Range | Adult: dose of carboplatin is determined according to renal function rather than body surface area. |
| Drug Interactions | |
| Pregnancy | Carboplatin can cause fetal toxicity when administered to pregnant women, but po More ... |
| Breast Feeding | Because of the potential for serious adverse reactions to carboplatin in nursing More ... |
| Active Ingredient | CHLORAMBUCIL |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Chronic lymphocytic leukemia, lymphomas |
| Caution | Anorexia, nausea, leukop enia, throm-bocytopenia, anaemia. Drink 6-8 glasses of liquid everyday.Avoid aspirin or medication containing aspirin. |
| Dose Range | 0.1-0.2mg/kg/day (usually 4-10mg once daily ) for 3-4 weeks. |
| Drug Interactions | |
| Pregnancy | Chlorambucil can cause fetal harm when administered to pregnant women, but poten More ... |
| Breast Feeding | Discontinue breast-feeding. |
| Active Ingredient | CISPLATIN |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Treatment of testicular, lung, cervical, bladder, head and neck, and ovarian cancer. |
| Caution | Alop ecia, bone-marrow suppression,extravasation, hyperuricaemia, hypomagnesaemia, myelosuppression, nephrotoxicity severe nausea, severe vomiting. |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | Cisplatin may cause fetal harm when administered to a pregnant woman but potenti More ... |
| Breast Feeding | Cisplatin is distributed into milk. Nursing should be discontinued to avoid the More ... |
| Active Ingredient | CYCLOPHOSPHAMIDE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Non-Hodgkin’s lymphomas. |
| Caution | High fluid intake will help to prevent haemorrhagic cystitis (3-4 litres/day ). C.f. prescribing in renal disease p. 27. |
| Dose Range | Low-dose: 2-6 mg/kg weekly as a single i.v. dose/ in divided oral doses; moderate-dose:10-15 mg/kg weekly as a single i.v. dose; High-dose: 20-40 mg/kg as a single i.v. dose every 10-20 days, depending on the disease being treated, condi |
| Drug Interactions | |
| Pregnancy | Cyclophosphamide can cause fetal toxicity when administered to pregnant women, b More ... |
| Breast Feeding | Discontinue breast-feeding during and for 36 hours after stopping treatment. |
| Active Ingredient | CYCLOSPORIN |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Prophylaxis of graft rejection in Organ and tissue transplantation. |
| Caution | Abdominal pain; anorexia; diarrhoea; fatigue; gingival hyperplasia; headache; hepatic dysfunction. Renal dysfunction (renal structural changes on long-term administration). |
| Dose Range |
Ciclosp orin is 10 to 15 mg/kg daily , beginning 4 to 12 hours before transp lantation, and continued for 1 to 2 weeks. maintenance 2-6 mg/kg daily, reduce dose gradually to maintenance |
| Drug Interactions | |
| Pregnancy | Cyclosporin crosses the placenta; manufacturer advises to avoid unless potential More ... |
| Breast Feeding | Avoid breastfeeding during cyclosporin therapy. |
| Active Ingredient | CYPROTERONE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Advanced prostatic carcinoma. |
| Caution |
Impotence, inhibition of spermatogenesis, headache, gynecomastia, galactorrhea, weight gain, lipid abnormalities, gastrointestinal disturbances and anemia. Several cases of hep ato More ... |
| Dose Range | Palliative treatment: 200- 300 mg daily in 2 or 3 divided doses after meals. S uppression of disease flare: 100 mg twice daily used alone for 5 to 7 day s, then with a gonadorelin analogue for 3 to 4 weeks. |
| Drug Interactions | |
| Pregnancy | Use of cyproterone during pregnancy might carry a risk of feminisation of a male More ... |
| Breast Feeding |
| Active Ingredient | CYTARABINE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Induction of remission of acute myeloblastic leukaemia. |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | Cytarabine can cause fetal toxicity when administered to pregnant women, but pot More ... |
| Breast Feeding | Discontinue breast-feeding. |
| Active Ingredient | DACARBAZINE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Metastatic melanoma. |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | Dacarbazine should be used during pregnancy only when the potential benefits jus More ... |
| Breast Feeding | Discontinue breast-feeding. |
| Active Ingredient | DAUNORUBICIN |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Induction of remission of acute leukaemias. |
| Caution | Dose related myelosuppression, cardiotoxicity, alopecia, urine discoloration; extravasation. |
| Dose Range | 40 - 60 mg/m2 on alternate days for a course of up to 3 injections. |
| Drug Interactions | |
| Pregnancy | Daunorubicin may cause fetal harm when administered to a pregnant woman. Animal More ... |
| Breast Feeding | Discontinue breastfeeding. |
| Active Ingredient | DOCETAXEL |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Use as neoadjuvent with metastatic breast cancer. |
| Caution | As for Paclitaxel. |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | Docetaxel may cause fetal harm when administered to pregnant women, but potentia More ... |
| Breast Feeding | It is not known whether docetaxel is distributed into milk. |
| Active Ingredient | DOXORUBICIN |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Hodgkin's disease, non-Hodgkin's lymphomas, acute leukaemias. |
| Caution | Myelosuppression, reversible, alopecia, nausea, vomiting |
| Dose Range | 60-75mg/M 2 i.v. as a single injection every 3 or 4 weeks; or 1.2-2.4 mg/kg once every 3 weeks. |
| Drug Interactions | |
| Pregnancy | Doxorubicin can cause fetal toxicity when administered to pregnant women, but po More ... |
| Breast Feeding | Not recommended. |
| Active Ingredient | EPIRUBICIN |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Acute leukaemias, lymphomas, solid tumours. |
| Caution | Leukopenia, nausea and vomiting, diarrhoea, thrombocytopenia, EKG changes, congestive cardiac failure secondary to a diffuse cardiomyopathy, alopecia. C.f. prescribing in liver disease p. 13. |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | Avoid during pregnancy. Teratogenic effects and embryotoxicity were noted in ani More ... |
| Breast Feeding | It is unknown whether epirubicin is distributed in milk. Breastfeeding is theref More ... |
| Active Ingredient | ETOPOSIDE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Small cell carcinoma of the bronchus, the lymphomas and testicular cancer. |
| Caution | Alopecia; bone-marrow supp ression. |
| Dose Range | Adult: Orally , 120–240 mg/m2 daily for 5 days. |
| Drug Interactions | |
| Pregnancy | Etoposide may cause fetal harm when administered to pregnant women, but potentia More ... |
| Breast Feeding | Unknown. Breastfeeding is not recommended. |
| Active Ingredient | EVEROLIMUS |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | EXEMESTANE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Adjuvant treatment of oestrogen-receptor-positive early breast cancer in postmenop ausal women following 2–3 years of tamoxifen therapy Advanced breast cancer in postmenop ausal women in whom antioe More ... |
| Caution | Abdominal pain; alopecia; anorexia; constipation; depression; dizziness; dyspepsia; fatigue; headache; hot flushes; insomnia; nausea; rash; sweating; vomiting. |
| Dose Range | 25mg once a day after a meal. |
| Drug Interactions | |
| Pregnancy | Avoid during pregnancy. |
| Breast Feeding | Breastfeeding is not recommended during exemestane therapy. |
| Active Ingredient | FILGRASTIM |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Prevention of neutropenia in patients receiving myelosup pressive cancer chemotherapy and to reduce the period of neutropenia in patients undergoing bone marrow transplantation |
| Caution | Musculoskeletal pain, dysuria |
| Dose Range |
Adjunct to antineoplastic therapy, filgrastim is given in a dose of 5 micrograms/kg daily starting not less than 24 hours after t he last dose of antineop lastic. Bone marrow transp lantation is 10 micrograms/kg daily , adjusted according to response. |
| Drug Interactions | |
| Pregnancy | Use only if potential benefit to mother justifies the risk to the fetus. |
| Breast Feeding | Use with caution for lactating women. |
| Active Ingredient | FLUDARABINE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Initial treatment of advanced B-cell chronic lymphocytic leukaemia (CLL) or after first line treatment in patients with sufficient bone-marrow reserves. |
| Caution | Fludarabine has a potent immunosuppresive effect. Patients treated with fludarabine are more prone to serious bacterial, opportunistic fungal, and viral infections, and prophylactic therapy can be use More ... |
| Dose Range |
40 mg/m2 for 5 days every 28 days, usually given for 6 cycles. By intravenous injection, or by intravenous infusion. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | FLUOROURACIL |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Gastrointestinal cancer |
| Caution | Anorexia, nausea and vomiting, stomatitis, diarrhoea, thrombocytopenia, alopecia, dermatitis, skin hyperpigmentation. |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | Fluorouracil may cause fetal harm when administered to pregnant women. Animal st More ... |
| Breast Feeding | Not recommended during fluorouracil therapy. |
| Active Ingredient | FLUTAMIDE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Prostate cancer. |
| Caution | Gynecomastia and galactorrhea are the most frequently reported adverse effects and occur in up to 42% of patients. Other adverse effects include diarrhoea, nausea, vomiting and transient serum More ... |
| Dose Range | 250mg 3 times daily . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | GOSERELIN |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |